Earnings Call · Q3 FY2022·2022-11-10

Q3 22EPS +29.41%·Rev n/aQ2 22EPS +100.00%*·Rev n/aQ1 22EPS +28.57%·Rev n/aQ4 21EPS 0.00%·Rev n/a⚠ consensus missing

Dare Bioscience, Inc. DARE

Sabrina Johnson — Chief Executive Officer

204/214, first

DARE

RH1.

clindamycin phosphate

John Fair — Chief Business Officer

Lisa Walters-Hoffert — Chief Financial Officer

−2.2%1d on move date−7.7% vs SPY3d+4.3%5d−0.1%

Research tier

Behavioral profile computed for 7 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more DARE calls or request research access.

More DARE calls Browse calls Request research access